Essa Pharma Stock Filter Stocks by Fundamentals
| EPIX Stock | USD 6.72 0.35 4.95% |
ESSA Pharma fundamentals help investors to digest information that contributes to ESSA Pharma's financial success or failures. It also enables traders to predict the movement of ESSA Stock. The fundamental analysis module provides a way to measure ESSA Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ESSA Pharma stock.
ESSA | Shares Owned by Insiders |
ESSA Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of ESSA Pharma from analyzing ESSA Pharma's financial statements. These drivers represent accounts that assess ESSA Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ESSA Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 28.4M | 154.9M | 80.1M | 136.2M | 122.6M | 128.7M | |
| Enterprise Value | (21.2M) | 98.6M | 23.3M | 102.6M | 92.4M | 97.0M |
ESSA Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in ESSA Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ESSA Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ESSA Pharma's value.| Shares | Cibc World Markets Inc. | 2023-12-31 | 111.7 K | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 57.5 K | Royal Bank Of Canada | 2023-12-31 | 30.8 K | Geode Capital Management, Llc | 2023-12-31 | 26.9 K | Renaissance Technologies Corp | 2023-12-31 | 24.2 K | American Century Companies Inc | 2023-12-31 | 20 K | Privium Fund Management (uk) Ltd | 2023-12-31 | 20 K | Group One Trading, Lp | 2023-12-31 | 11.2 K | Blackrock Inc | 2023-12-31 | 7.7 K | Bvf Inc | 2023-09-30 | 8.7 M | Bellevue Group Ag | 2023-12-31 | 7.9 M |
ESSA Fundamentals
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 171.02 M | ||||
| Shares Outstanding | 44.24 M | ||||
| Shares Owned By Insiders | 2.20 % | ||||
| Shares Owned By Institutions | 78.71 % | ||||
| Number Of Shares Shorted | 802.84 K | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 2.48 X | ||||
| EBITDA | (26.46 M) | ||||
| Net Income | (26.58 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 80.33 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 3.19 X | ||||
| Cash Flow From Operations | (19.78 M) | ||||
| Short Ratio | 11.26 X | ||||
| Earnings Per Share | (0.59) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 50 | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 297.28 M | ||||
| Total Asset | 149.12 M | ||||
| Retained Earnings | (179.46 M) | ||||
| Working Capital | 145.3 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
| Net Asset | 149.12 M |
About ESSA Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ESSA Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ESSA Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ESSA Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ESSA Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ESSA Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ESSA Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against ESSA Stock
| 0.41 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to ESSA Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ESSA Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ESSA Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ESSA Pharma to buy it.
The correlation of ESSA Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ESSA Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ESSA Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ESSA Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ESSA Pharma Piotroski F Score and ESSA Pharma Altman Z Score analysis. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.13) | Return On Equity (0.17) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.